Woman slips into coma after AstraZeneca vaccine dose against Covid-19

Diagnosed with rare, serious condition

Coronavirus vaccines, booster shot
Representative Image
Agencies
2 min read Last Updated : Dec 05 2022 | 12:46 AM IST
A Covid jab, which has helped millions to fight the virus turned out to be a curse for a 46-year-old woman.  

Sarah Birch a mother of two was pushed to the brink, after she received the AstraZeneca vaccine against Covid-19 in May 2021 and later developed symptoms leading to her being in a coma for four days, according to Mirror report. Birch has been diagnosed with Guillain-Barré syndrome and spends her days in complete and utter pain.

Birch told Stoke-on-Trent Live, that she had received the AstraZeneca Covid-19 vaccine in May 2021. Following the jab, she started experiencing mild symptoms like dizziness, backache, and tingling in toes and tongue. After which she was addmited to a hospital.

There she was put on ventilation support for four days as Birch had slipped into a coma. 

Following this, Birch was diagnosed with Guillain-Barré syndrome. This rare disorder means that the patient's body's immune system attacks their nerves. Early symptoms include weakness and tingling in hands and feet. This can escalate quickly ultimately paralysing the whole body.

An AstraZeneca spokesperson has said, “The safety of anyone taking AstraZeneca’s vaccine is paramount and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines."

The UK government website claims that as of 26 October, over 24.9 million first doses of the AstraZeneca vaccine have been administered since its roll out in January last year. The same source also states that there have been 246,638 reports of suspected adverse reactions to the jab in the UK.

In a trial in which more than 23,000 patients were given the AstraZeneca vaccine, the most commonly reported side effects included headaches, fatigue, fever, chills and nausea.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineUKAstraZeneca

Next Story